NeuroDerm (NDRM) Says in Head-to-Head Trial ND0612H Achieves Comparable Pharmacokinetics to DUODOPA
Tweet Send to a Friend
NeuroDerm Ltd. (Nasdaq: NDRM) announced that topline results from Trial 005, a pilot, dose-finding pharmacokinetic (PK) study on healthy subjects ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
